Targeted Drug Delivery for Personalized Cure
- 385 Downloads
Human population bears a similarity to an extent of 99.9%, however mere 0.1% of variability also creates large differences in personal make-up owing to several hereditary and environmental factors. Conventionally, development of healthcare modalities like diagnostics and therapeutics has been by mass production assuming uniformity in characteristics of recipient population. Due to the inherent variability in each individual clinical response to diagnostic and therapeutic products vary greatly ranging from inefficient therapeutic compliance, adverse reactions and hypersensitivity reactions. Personalization of medications is the need of hour to avoid perils of both modalities so that efficient healthcare is provided to human population. Advances in delivery like targeted drug formulations, companion diagnostics and triggered drug formulations provide necessary dimensions to personalized medicines. Formulations with these capabilities can be described as theranostics and have been instrumental in this decade to establish the field of personalized medicine. The current chapter reviews different types, mechanisms of targeted and triggered drug delivery systems that have helped to improve the diagnostic and therapeutic compliance in disease management.
KeywordsTargeted drug delivery Passive targeting Active targeting Triggered delivery
Abhijeet Joshi acknowledges the INSPIRE Faculty award and fellowship provided by Department of Science and Technology, Government of India. Authors would also like acknowledge financial support from DBT and SERB.
- 1.Jain KK. Textbook of personalized medicine. 2nd ed. Berlin: Springer; 2015.Google Scholar
- 2.Personalized Medicine Coalition. 2015. http://www.personalizedmedicinecoalition.org/News/Press_Releases/More_Than_1_in_4_Novel_New_Drugs_Approved_by_FDA_in_2015_are_Personalized_Medicines. Accessed Sept 2017.
- 11.Tozaki H, Odoriba T, Okada N, Fujita T, Terabe A, Suzuki T, Okabe S, Muranishi S, Yamamoto A. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J Control Release. 2002;82(1):51–61. doi: 10.1016/S0168-3659(02)00084-6.CrossRefPubMedGoogle Scholar
- 14.Qin Y, Chen H, Zhang Q, Wang X, Yuan W, Kuai R, Tang J, Zhang L, Zhang Z, Zhang Q, Liu J, He Q. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm. 2011;420(2):304–12. doi: 10.1016/j.ijpharm.2011.09.008.CrossRefPubMedGoogle Scholar
- 23.Son YJ, Jang J-S, Cho YW, Chung H, Park R-W, Kwon IC, Kim I-S, Park JY, Seo SB, Park CR, Jeong SY. Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. J Control Release. 2003;91(1-2):135–45. doi: 10.1016/S0168-3659(03)00231-1.CrossRefPubMedGoogle Scholar
- 28.Ogawara K-i, Yoshida M, Higaki K, Toshikiro K, Shiraishi K, Nishikawa M, Takakura Y, Hashida M. Hepatic uptake of polystyrene microspheres in rats: effect of particle size on intrahepatic distribution. J Control Release. 1999;59(1):15–22. doi: 10.1016/S0168-3659(99)00015-2.CrossRefPubMedGoogle Scholar